Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Saniona AB (publ)    SANION   SE0005794617

SANIONA AB (PUBL)

(SANION)
  Report
Delayed Quote. Delayed NASDAQ OMX STOCKHOLM - 06/05 04:19:03 am
26.5 SEK   -1.30%
05/26Saniona announces outcome of warrant exercise
GL
05/22INITIATOR PHARMA : 1 quarter report 2020
AQ
05/11BIOSTOCK :  Saniona trailblazing towards market approval
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

INITIATOR PHARMA: 1 QUARTER REPORT 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 02:31am EDT

Clinical progress and expanded pipeline

Business highlights in Q1 2020

· On March 15[th] we reported the final data from the company's Phase 2a study with IPED2015, demonstrating statistically significant and clinically relevant results on key efficacy endpoints in patients with severe ED after a single administration of IPED2015. As previously reported, the Phase 2a study was completed satisfactorily with no observations of critical adverse events. 
· On March 31st we announced that we have filed a Phase 2a Clinical Trial Application (CTA) to MHRA, UK, for our candidate drug IP2018. Through the submission of the CTA, we also exercised our option agreement with Saniona for IP2018.

Significant events after this reporting period­

· On April 27[th] we announced that we have completed a SEKM 3 direct share issue with warrants to Formue Nord, a Danish investment fund, and also announced a proposal to the Annual General Meeting for a SEKM 7 rights issue with warrants that has been fully guaranteed. 

Financial Highlights

Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016

First Quarter (2020-01-01 - 2020-03-31)

· Net revenues were TDKK 0 (0)

· EBIT was TDKK -2,392 (-1,463)

· Earnings per share was DKK -0.11 (-0.22)

· Cash and bank: TDKK 7,082 (13,346)

· Solidity: 82%

Group earnings per share: period result divided by a number of 23 591 375 stocks (on 2020-03-31). Solidity: equity divided by assets. 

Comments from the CEO

"Q1 has been another eventful quarter for Initiator Pharma: First of all we announced the final data from the IPED2015 Phase 2a clinical trial with IPED2015. Secondly, we filed a Clinical Trial Application (CTA) to the UK regulatory body: the filing also allowed us to exercise the option on IP2108 with Saniona and we can now fully integrate the compound into the Initiator Pharma pipeline. 2020 will be a truly exciting year for the company, with a series of upcoming inflection events in the near to mid-term future"

For more information, please contact

Claus Olesen, CEO, Initiator Pharma, Mobile: +45-61 26 00 35, E-mail: ceo@initiatorpharma.com

Torgeir Vaage, CFO, Initiator Pharma, Mobile: +47-924 05 235, E-mail: tv@initiatorpharma.com

About Initiator Pharma 

Initiator Pharma A/S is a Danish biotechnology company focusing on the development of innovative drugs, targeting key unmet medical needs within the central and peripheral nervous system. Our research is focusing on monoamine reuptake inhibitors, molecules that are affecting the synaptic concentrations of neurotransmitters such as dopamine, serotonin and noradrenaline. Our lead candidate drug, IPED2015 is targeting the medical condition Erectile Dysfunction (ED), and specifically patients with ED that are non-responsive to drugs within the PDE5i class, including the approved drugs ViagraÓ, CialisÓ and LevitraÓ.

Initiator Pharma is based in Aarhus, Denmark.  Initiator Pharma is listed on Spotlight Stockmarket and has about 3.800 shareholders. Read more at www.initiatorpharma.com.

https://news.cision.com/initiator-pharma/r/initiator-pharma--1-quarter-report-2020,c3116908

https://mb.cision.com/Main/15335/3116908/1251292.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANIONA AB (PUBL)
05/26Saniona announces outcome of warrant exercise
GL
05/22INITIATOR PHARMA : 1 quarter report 2020
AQ
05/11BIOSTOCK :  Saniona trailblazing towards market approval
AQ
05/07Saniona announces that the exercise period of warrants of series TO 1 begins ..
GL
05/06Bulletin from the annual shareholders' meeting on may 6, 2020 in saniona ab
GL
05/06Saniona publishes its interim report for the first quarter 2020
GL
05/05BIOSTOCK :  CEO Saniona »The real growth will come from our proprietary projects..
AQ
04/27SANIONA IS INVITING INVESTORS TO PAR : Tesomet for the Treatment of Hypothalamic..
GL
04/27SANIONA : appoints Rudolf Baumgartner, M.D., as Chief Medical Officer and Head o..
AQ
04/22Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hyp..
GL
More news
Financials
Sales 2020 87,0 M 9,51 M 9,51 M
Net income 2020 -16,0 M -1,75 M -1,75 M
Net cash 2020 68,0 M 7,43 M 7,43 M
P/E ratio 2020 -50,7x
Yield 2020 -
Capitalization 816 M 88,6 M 89,1 M
EV / Sales 2019
EV / Sales 2020 8,60x
Nbr of Employees 22
Free-Float 68,4%
Chart SANIONA AB (PUBL)
Duration : Period :
Saniona AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANIONA AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 110,00 SEK
Last Close Price 26,85 SEK
Spread / Highest target 310%
Spread / Average Target 310%
Spread / Lowest Target 310%
EPS Revisions
Managers
NameTitle
Rami Levin President & Chief Executive Officer
Joseph Donald deBethizy Chairman
Anita Milland Chief Financial Officer
Palle Christophersen Chief Scientific Officer
Rudolf A. Baumgartner Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
SANIONA AB (PUBL)4.47%89
GILEAD SCIENCES19.33%93 325
VERTEX PHARMACEUTICALS24.60%71 822
REGENERON PHARMACEUTICALS59.41%61 367
WUXI APPTEC CO., LTD.23.71%19 498
GENMAB A/S31.49%19 164